Generic semaglutide has arrived on pharmacy shelves across Canada, with prices for the medication now roughly $100 per month [1].
This price drop expands access to GLP-1 therapy for patients who previously found the brand-name drug financially prohibitive. The availability of a lower-cost alternative is expected to drive up demand for weight loss and diabetes treatment nationwide [1, 3].
The generic version is available at select pharmacy locations, including Shoppers Drug Mart and Rexall [1, 2]. The medication is chemically identical to the brand-name product and meets all Health Canada standards, a Health Canada official said [3].
Cost comparisons highlight a decline in patient spending. While brand-name Ozempic costs approximately $400 per month [3], the generic version is priced at about $100 per month [1]. An Apotex spokesperson said the company's price is less than a third of the brand-name Ozempic [3].
Pharmacy staff report a surge in interest following the launch. "We’re seeing a lot of interest from patients who couldn’t afford the brand-name drug," a pharmacy representative said [1].
The rollout of generic semaglutide follows a period of high demand and supply constraints for the brand-name version. By offering a chemically equivalent option at a fraction of the cost, the market shift aims to alleviate the financial burden on Canadians seeking metabolic health treatments [1, 3].
“The generic is chemically identical to the brand-name product and meets all Health Canada standards.”
The introduction of generic semaglutide marks a pivotal shift in the affordability of GLP-1 agonists in Canada. By reducing the monthly cost from approximately $400 to $100, the barrier to entry for chronic weight management and type 2 diabetes treatment is lowered. This likely increases the volume of patients qualifying for therapy, which may put further pressure on national supply chains while simultaneously improving public health outcomes through wider medication adherence.
